| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/20/2023 | 325.59% | HC Wainwright & Co. | $12 → $3 | Maintains | Buy |
| 11/09/2023 | — | TD Cowen | Downgrades | Outperform → Market Perform | |
| 11/08/2023 | 751.18% | RBC Capital | $7 → $6 | Maintains | Outperform |
| 09/19/2023 | 1602.37% | HC Wainwright & Co. | → $12 | Reiterates | Buy → Buy |
| 09/12/2023 | 1034.91% | RBC Capital | $9 → $8 | Maintains | Outperform |
| 08/10/2023 | — | JP Morgan | Upgrades | Underweight → Neutral | |
| 08/09/2023 | 1176.78% | RBC Capital | $10 → $9 | Maintains | Outperform |
| 07/25/2023 | 1602.37% | HC Wainwright & Co. | → $12 | Reiterates | Buy → Buy |
| 07/11/2023 | 183.73% | Morgan Stanley | $5 → $2 | Reiterates | Equal-Weight → Equal-Weight |
| 06/20/2023 | 1602.37% | HC Wainwright & Co. | $20 → $12 | Maintains | Buy |
| 05/10/2023 | 1318.64% | RBC Capital | $12 → $10 | Maintains | Outperform |
| 04/24/2023 | 183.73% | B of A Securities | $7 → $2 | Downgrades | Neutral → Underperform |
| 02/13/2023 | 1602.37% | RBC Capital | $18 → $12 | Maintains | Outperform |
| 01/24/2023 | 609.32% | Morgan Stanley | $7 → $5 | Maintains | Equal-Weight |
| 01/04/2023 | 2737.28% | HC Wainwright & Co. | $21 → $20 | Maintains | Buy |
| 11/14/2022 | 893.05% | Morgan Stanley | $11 → $7 | Maintains | Equal-Weight |
| 11/09/2022 | 2737.28% | RBC Capital | $25 → $20 | Maintains | Outperform |
| 11/09/2022 | 893.05% | B of A Securities | $14 → $7 | Downgrades | Buy → Neutral |
| 09/21/2022 | 609.32% | JP Morgan | → $5 | Initiates Coverage On | → Overweight |
| 09/19/2022 | 2879.15% | HC Wainwright & Co. | $20 → $21 | Maintains | Buy |
| 09/09/2022 | 1460.51% | Morgan Stanley | $17 → $11 | Downgrades | Overweight → Equal-Weight |
| 08/22/2022 | 2737.28% | HC Wainwright & Co. | $44 → $20 | Maintains | Buy |
| 08/10/2022 | 4014.06% | RBC Capital | $30 → $29 | Maintains | Outperform |
| 07/11/2022 | 6142.02% | HC Wainwright & Co. | $54 → $44 | Maintains | Buy |
| 05/10/2022 | 2311.69% | Morgan Stanley | $30 → $17 | Maintains | Overweight |
| 05/10/2022 | 4155.92% | RBC Capital | $34 → $30 | Maintains | Outperform |
| 04/12/2022 | 4155.92% | Morgan Stanley | $29 → $30 | Maintains | Overweight |
| 03/04/2022 | 7560.66% | HC Wainwright & Co. | $55 → $54 | Maintains | Buy |
| 02/01/2022 | 4014.06% | Morgan Stanley | $47 → $29 | Maintains | Overweight |
| 11/09/2021 | 6142.02% | Wolfe Research | → $44 | Initiates Coverage On | → Outperform |
| 11/03/2021 | 4723.38% | RBC Capital | $33 → $34 | Maintains | Outperform |
| 09/07/2021 | 6567.61% | Morgan Stanley | $51 → $47 | Maintains | Overweight |
| 08/09/2021 | 4581.52% | RBC Capital | → $33 | Initiates Coverage On | → Outperform |
| 07/16/2021 | 7135.07% | Morgan Stanley | $53 → $51 | Maintains | Overweight |
| 06/15/2021 | 6425.75% | Cantor Fitzgerald | → $46 | Initiates Coverage On | → Overweight |
| 05/14/2021 | 7702.53% | HC Wainwright & Co. | $57 → $55 | Maintains | Buy |
| 05/10/2021 | 7418.8% | Morgan Stanley | $55 → $53 | Maintains | Overweight |
| 04/26/2021 | 7986.25% | HC Wainwright & Co. | $48 → $57 | Maintains | Buy |
| 03/23/2021 | 7702.53% | Morgan Stanley | $56 → $55 | Maintains | Overweight |
| 03/19/2021 | 6709.48% | HC Wainwright & Co. | $47 → $48 | Maintains | Buy |
| 12/16/2020 | 7844.39% | Morgan Stanley | $52 → $56 | Maintains | Overweight |
| 12/03/2020 | 5858.29% | Stifel | → $42 | Initiates Coverage On | → Hold |
| 10/29/2020 | 6567.61% | HC Wainwright & Co. | → $47 | Initiates Coverage On | → Buy |
| 10/13/2020 | 7276.93% | Morgan Stanley | $53 → $52 | Maintains | Overweight |
| 06/09/2020 | 7418.8% | Morgan Stanley | → $53 | Initiates Coverage On | → Overweight |
| 06/09/2020 | — | Cowen & Co. | Initiates Coverage On | → Outperform |
What is the target price for ADC Therapeutics (ADCT)?
The latest price target for ADC Therapeutics (NYSE: ADCT) was reported by HC Wainwright & Co. on November 20, 2023. The analyst firm set a price target for $3.00 expecting ADCT to rise to within 12 months (a possible 325.59% upside). 15 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for ADC Therapeutics (ADCT)?
The latest analyst rating for ADC Therapeutics (NYSE: ADCT) was provided by HC Wainwright & Co., and ADC Therapeutics maintained their buy rating.
When is the next analyst rating going to be posted or updated for ADC Therapeutics (ADCT)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of ADC Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for ADC Therapeutics was filed on November 20, 2023 so you should expect the next rating to be made available sometime around November 20, 2024.
Is the Analyst Rating ADC Therapeutics (ADCT) correct?
While ratings are subjective and will change, the latest ADC Therapeutics (ADCT) rating was a maintained with a price target of $12.00 to $3.00. The current price ADC Therapeutics (ADCT) is trading at is $0.70, which is out of the analyst's predicted range.